1. Home
  2. SAGE vs ACCO Comparison

SAGE vs ACCO Comparison

Compare SAGE & ACCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAGE
  • ACCO
  • Stock Information
  • Founded
  • SAGE 2010
  • ACCO 1893
  • Country
  • SAGE United States
  • ACCO United States
  • Employees
  • SAGE N/A
  • ACCO N/A
  • Industry
  • SAGE Biotechnology: Pharmaceutical Preparations
  • ACCO Publishing
  • Sector
  • SAGE Health Care
  • ACCO Consumer Discretionary
  • Exchange
  • SAGE Nasdaq
  • ACCO Nasdaq
  • Market Cap
  • SAGE 462.2M
  • ACCO 503.9M
  • IPO Year
  • SAGE 2014
  • ACCO N/A
  • Fundamental
  • Price
  • SAGE $5.00
  • ACCO $5.75
  • Analyst Decision
  • SAGE Hold
  • ACCO Buy
  • Analyst Count
  • SAGE 20
  • ACCO 1
  • Target Price
  • SAGE $12.89
  • ACCO $7.00
  • AVG Volume (30 Days)
  • SAGE 854.9K
  • ACCO 701.1K
  • Earning Date
  • SAGE 10-29-2024
  • ACCO 10-31-2024
  • Dividend Yield
  • SAGE N/A
  • ACCO 5.34%
  • EPS Growth
  • SAGE N/A
  • ACCO N/A
  • EPS
  • SAGE N/A
  • ACCO N/A
  • Revenue
  • SAGE $106,399,000.00
  • ACCO $1,706,700,000.00
  • Revenue This Year
  • SAGE N/A
  • ACCO N/A
  • Revenue Next Year
  • SAGE $118.26
  • ACCO $1.35
  • P/E Ratio
  • SAGE N/A
  • ACCO N/A
  • Revenue Growth
  • SAGE 837.60
  • ACCO N/A
  • 52 Week Low
  • SAGE $4.62
  • ACCO $4.37
  • 52 Week High
  • SAGE $28.26
  • ACCO $6.62
  • Technical
  • Relative Strength Index (RSI)
  • SAGE 32.20
  • ACCO 51.43
  • Support Level
  • SAGE $4.62
  • ACCO $5.58
  • Resistance Level
  • SAGE $5.87
  • ACCO $6.44
  • Average True Range (ATR)
  • SAGE 0.39
  • ACCO 0.21
  • MACD
  • SAGE -0.10
  • ACCO -0.04
  • Stochastic Oscillator
  • SAGE 21.18
  • ACCO 36.31

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

About ACCO Acco Brands Corporation

ACCO Brands Corp designs, manufactures, and markets consumer and business products. It operates through three segments: ACCO Brands North America, ACCO Brands EMEA, and ACCO Brands International. The company offers school notebooks, janitorial supplies, and whiteboards; storage and organization products, sheet protectors, and indexes, and punching products; computer accessories and others used in schools, homes, and businesses. It offers its products under the AT-A-GLANCE, Five Star, GBC, Hilroy, Kensington, Quartet, Leitz, NOBO and other brands. The company markets and sells its products through various channels, including mass retailers; e-tailers; discount, and variety chains; and warehouse clubs. It generates maximum profit from ACCO Brands North America segment.

Share on Social Networks: